Savara (SVRA) said Thursday it has launched its aPAP ClearPath dried blood spot test in the US.
The test is designed to help obtain a diagnosis of aPAP, a rare autoimmune lung disease, through a finger-prick blood sample, the company said.
The DBS test has achieved 100% sensitivity and specificity in a group of individuals with aPAP autoantibody status, Savara said.
Shares were almost 2% higher in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。